Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (362)	5/12/1998 12:11:00 PM
From: David Bogdanoff	Respond to of 507

C: Other postings on this thread have stated that NVX won an important patent case in the early 90's, I believe. Thus, NVX has key patent protection, imo. Thanks for discussing some of Sturza's points, incorrect as they seem to be. David

To: Cacaito who wrote (362)	5/12/1998 12:16:00 PM
From: Don W Stone	Read Replies (1) \| Respond to of 507

cacaito: Thanks for sharing your thoughts on your recent attendence at the Society of Pediatrics annuial meeting. You asked: << Don, What are the chances that other companies will quickly follow NVX strategy: MONOCOMPONENT toxoid vaccine? Is NVX protected by any patent? >>> Here is your answer as it is stated right from the NVX '97 annual report. " This vaccine technolgy was developed and patented at the National Institute of Child health and Human Development ( NICHD), and the world wide rights have been granted exclusively to North American Vaccine." I would say that it is not likely that any company will follow NVX's strategy . By the time they would have a product to market NVX will be marketing a multi combination vaccine DTaP-IPV-Hib-MenA,B,C